Vaxcyte appointed John Markels to its Board as Class II director effective July 16, 2026, concurrent with Heath Lukatch's retirement from the Board.
| IndividualHeath LukatchJohn Markels | RoleBoard memberClass II director; member of Audit Committee and Compensation Committee | Type of ChangeRetiredAppointed | Effective DateJuly 16, 2026July 16, 2026 | ReasonRetirement; not due to any disagreement or dispute with the CompanyAppointment by Board upon recommendation of the Nominating and Corporate Governance Committee | Replacement InfoJohn Markels appointed to BoardNot disclosed | Background DetailsMore than eight years of Board service (contribution acknowledged)Qualifies as independent under Nasdaq Rule 5605(a)(2); no arrangements or reportable transactions; will receive standard non-employee director compensation including annual equity grant value currently set at $430,000; standard indemnification agreement entered | Board/Committee Role ChangesNot disclosedAppointed to Audit Committee and Compensation Committee |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.